
Guillem Esteve Boncompte is a third-year Dermatology Medical-Surgical and Venereology resident (R3) at Hospital Universitari Arnau de Vilanova in Lleida, Spain, with a strong clinical and research profile. He is highly engaged in academic dermatology, currently leading and contributing to multiple research projects including a case series on lentigo maligna treated with immunocryosurgery and several systematic reviews in dermatology and genodermatoses. He has a particular interest in dermoscopy, lasers, digital dermatology, and artificial intelligence applied to skin disease, and actively seeks national and international training opportunities to broaden his expertise. Proactive in scientific communication and professional networking, he combines clinical practice with a rigorous, methodical approach to research, data analysis, and academic writing, aiming to contribute to innovation and evidence-based dermatology.
My main areas of interest include dermatologic surgery and Mohs micrographic surgery where I am particularly motivated to deepen my technical skills and improve oncologic and cosmetic outcomes for patients with skin cancer. I am strongly interested in cutaneous neoplasms both in their clinical management and in advancing diagnostic and therapeutic strategies through research and innovation. In parallel I am enthusiastic about the application of artificial intelligence in dermatology especially for improving diagnostic accuracy triage and digital imaging in skin cancer and inflammatory diseases. I am also keenly interested in psoriasis with a focus on personalized treatment approaches emerging biologic therapies and the integration of digital tools to optimize patient care and long-term disease management.
Photoprotection is a fundamental public health strategy to prevent sunburn, photoaging, actinic damage, and skin cancer, whose incidence is largely driven by ultraviolet (UV) radiation. Solar radiation includes UVA, UVB, visible light, and infrared; UVB is the main driver of DNA damage and carcinogenesis, while UVA contributes substantially to photoaging and melanoma risk. Effective photoprotection requires daily use of broad-spectrum sunscreens (UVA/UVB), applied at an adequate thickness (≈2 mg/cm²) and reapplied every 2–3 hours, complemented by behavioral measures such as seeking shade, wearing protective clothing, and avoiding peak sun hours. Sunscreens can be physical (zinc oxide, titanium dioxide) or chemical (e.g., benzophenones, octocrylene, octinoxate), each with advantages and limitations regarding cosmetic acceptability, skin tolerance, systemic absorption, and environmental impact. While chemical filters can be detected systemically and raise concerns about endocrine effects and marine toxicity, current evidence supports that the benefits of sunscreen use in preventing skin cancer clearly outweigh potential risks. Special populations—light phototypes, children, pregnant women, immunosuppressed patients, and individuals with photosensitive dermatoses or prior skin cancer—require stricter photoprotection (SPF 50+). Finally, sunscreen use does not preclude adequate vitamin D synthesis under real-world conditions, and supplementation is recommended only in high-risk groups practicing strict photoavoidance.
Objectives: To systematically review and synthesize the available evidence on clinical response, treatment regimens, relapse, and adverse e…
Objectives: To systematically review and synthesize the available evidence on clinical response, treatment regimens, relapse, and adverse e…